Enter your email address and we’ll send you MarketBeat’s list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Provides a general description of the business conducted by this company.
New: Manage All Your Stock Portfolios in One Place
We believe this progress derisks our upcoming IND submission and offers flexibility to potentially expand our current Phase 1b trial. We look forward to ongoing engagement with the FDA as we advance these critical efforts and will leverage the experience of our newly formed Clinical Advisory Board as needed. In December 2024, we received approval to initiate our Phase 1b clinical trial of GT in people with GBA1 or idiopathic Parkinson’s disease.
Part of StoneX Group, Inc., GTX SEF LLC is a company that provides online foreign exchange trading services. With 2025 poised to be another pivotal year for Gain Therapeutics, I want to take a moment to provide an update on the key milestones we are expecting to achieve in 2025. Building on the accomplishments and dedicated work of the entire Gain team in 2024, we continue to advance the clinical development of GT-02287, a potentially disease-modifying therapy for Parkinson’s disease (PD) in people with or without a GBA1 mutation. While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. While there is some analyst coverage, the company is probably not widely covered.
Reader services
About Gain Therapeutics, Inc.Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation. Results from a Phase 1 study of GT in healthy volunteers demonstrated favorable safety and tolerability, plasma exposure in the projected therapeutic range, CNS exposure, and target engagement and modulation of GCase enzyme. We believe that our Phase 1b clinical trial will illustrate that the broad neuroprotective effect demonstrated in pre-clinical models of Parkinson’s disease will translate to human participants with Parkinson’s 11 sectors of the stock market disease. We believe this may unlock significant value for the GT development program through 2025 and beyond. The fight against Parkinson’s disease is one we at Gain are truly committed to.
Information is provided ‘as is’ and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab). Part of StoneX Group, Inc., StoneX Financial Pty Ltd. is an Australian company that distributes electronic goods related to stock trading. Sean Michael O’Connor has been the CEO of the company since 2002. Highlights important summary options statistics to provide a forward looking indication of investors’ sentiment.
Company Overview
I’m inspired by the dedication of our team and grateful to share this important mission with you. I look forward to keeping you updated as we progress through the year and thank you for your support along the way. As a reminder, we are planning on enrolling individuals with either GBA1 or idiopathic Parkinson’s disease – all of whom will receive oral GT daily for three months in the open-label Phase 1b clinical trial. We plan to evaluate different biomarkers of Parkinson’s disease from the cerebrospinal fluid and plasma samples taken from participants at baseline and completion of the study. The Barchart just2trade review Technical Opinion widget shows you today’s overall Barchart Opinion with general information on how to interpret the short and longer term signals. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods.
Daniels Trading Unveils New StoneX Brand & Services
It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Microvast Holdings, (below). Of course, keep in mind that there are other factors to consider, too. In 2025, we will remain focused on strengthening our collaboration with the FDA and other regulatory authorities to expand the clinical development of GT within the U.S. In early December 2024, we held a productive pre-IND meeting with the FDA and received encouraging feedback that aligned with our expectations. Notably, the FDA did not identify any significant regulatory hurdles that could delay our preparations for Phase 2.
- Of course, keep in mind that there are other factors to consider, too.
- Part of StoneX Group, Inc., GTX SEF LLC is a company that provides online foreign exchange trading services.
- Alternatively, those holders might be exiting the investment after taking it public.
- However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
- Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature.
- Provides a general description of the business conducted by this company.
Company Info
Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy. I generally consider insider ownership to be a good thing.
While this group can’t necessarily call the shots, it can certainly have a real influence on how the company is run. Retail investors gained the most after market cap touched US$638m last week, while insiders who own 29% also benefitted. Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function.
- While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing.
- The definition of company insiders can be subjective and does vary between jurisdictions.
- We plan to evaluate different biomarkers of Parkinson’s disease from the cerebrospinal fluid and plasma samples taken from participants at baseline and completion of the study.
- Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd.
- Compelling preclinical data in models of both GBA1-PD and idiopathic PD, demonstrating a disease-modifying effect after administration of GT-02287, suggests that GT may have the potential to slow or stop the progression of Parkinson’s disease.
- In December 2024, we received approval to initiate our Phase 1b clinical trial of GT in people with GBA1 or idiopathic Parkinson’s disease.
- In early December 2024, we held a productive pre-IND meeting with the FDA and received encouraging feedback that aligned with our expectations.
Our clinical team led by Gain’s Chief Medical Officer, Jonas Hannestad, is currently working closely with seven clinical centers in Australia to begin dosing the first patients in the Phase 1b clinical trial, which we expect to happen imminently. We expect to provide an enrollment update by the end of 1Q 2025 and guidance in 2Q 2025 when we expect to be in position to discuss interim analysis of the Phase 1b clinical trial. Private equity firms hold a 13% stake in Microvast Holdings. This suggests they can be influential in key policy decisions. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.
It provides services to retail customers through FOREX.com and Cityindex.com, as well as through brokers and white label partners. The company offers execution and risk management services for exchange-traded futures and futures options on the United States and European futures and options exchanges; and online trading services. GAIN Capital Holdings, Inc. was founded in 1999 and is headquartered in Bedminster, New Jersey. Institutional foreign exchange, trading and related services providing direct access to the global OTC foreign exchange markets, where participants trade directly with one another. Its trading platforms provide information and analytical tools that allow customers to identify, analyze and execute their trading strategies. GAIN also offers retail customers located outside the United States access to other global markets on an OTC basis, including the spot gold and silver markets, as well as equity indices and commodities.
GAIN Capital Holdings, Inc., together with its subsidiary, provides trading services and solutions to retail, https://www.forex-world.net/ institutional, and futures service customers worldwide. The company operates in two segments, Retail and Futures. It specializes in over-the-counter (OTC) and exchange-traded markets.
Bacharelanda em Letras (Inglês-Português) que escreve desde o dia em que aprendeu segurar a caneta.